Biopsy Devices Market Report 2025

The biopsy devices market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to emerging markets growth, advancement in healthcare infrastructure, and growth in the elderly population.

The biopsy devices market size is expected to see strong growth in the next few years. It will grow to $4.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to government investments in the healthcare sector, rising cancer cases and an increase in healthcare expenditure will drive the market growth. Major trends in the forecast period include technological advancements, the launch of fully automatic biopsy systems, product innovations, the development of robot-assisted biopsy systems, partnerships and collaborations, and increasing investments.

The escalation in cancer incidences has significantly contributed to the expansion of the biopsy devices market, as biopsies remain a primary diagnostic method used by medical professionals when suspecting the presence of cancer cells in the body. Notably, statistics from the American Cancer Society in January 2023 revealed an anticipated 1.9 million new cancer cases diagnosed in the United States in 2022, with an estimated 609,360 cancer-related deaths. Specifically, projections indicated around 151,030 new cases of colorectal cancer by the close of 2022, estimated to result in roughly 52,550 deaths in 2023. Additionally, a May 2022 report from the Canadian Medical Association Journal highlighted an estimated 233,900 new cancer cases in Canada for 2022, with approximately 28,600 projected to be breast cancer cases, constituting about 25% of all newly diagnosed cases in women. Lung cancer was expected to be the most prevalent type in Canada, with an estimated 30,000 new cases.

An increasing number of surgeries is anticipated to drive the growth of the biopsy devices market. Surgery is a medical field dedicated to treating injuries, illnesses, and various disorders through manual and instrumental techniques. Biopsy devices are commonly used in surgical procedures to extract small tissue samples or clusters of cells for further laboratory examination. For example, in March 2023, the British Association of Aesthetic Plastic Surgeons, a UK-based surgical organization, reported that 31,057 cosmetic surgeries were performed in the UK in 2022, representing a significant 102% rise from the previous year. Additionally, a report from Austin Publishing Group, a US-based publishing company, indicated that over 300 million major procedures are carried out globally each year. Consequently, the increasing number of surgeries is fueling the growth of the biopsy devices market moving forward.

Robot-assisted biopsy systems are revolutionizing the landscape of the biopsy devices market by offering improved precision and a reduced risk of complications post-biopsy. These systems aim to enhance the accuracy of biopsy procedures, earning approvals from medical regulatory bodies for their contribution to simplifying and refining the process. Notably, in July 2022, the FDA granted clearance for Siemens Healthineers’ and Intuitive’s platforms to develop a robotic-assisted platform specifically tailored for minimally invasive lung biopsies. This integration facilitates both 2D and 3D imaging capabilities during the biopsy procedures.

Leading companies in the biopsy devices market are developing innovative products like dual-stage core biopsy systems to enhance their profitability. The dual-stage core biopsy system is a medical device that obtains larger, intact tissue samples in two phases, allowing for more precise and accurate diagnoses, especially in cancer cases. This dual-stage approach improves both the quality of the samples and the efficiency of the procedure. For example, in August 2022, Mammotome, a US-based provider of vacuum-assisted breast biopsy devices, introduced its Mammotome DualCore. This advanced system aims to improve the efficiency and accuracy of breast biopsy procedures, providing healthcare professionals with state-of-the-art tools to better facilitate patient care.

In June 2023, Quest Diagnostics, a US-based medical laboratories company, successfully acquired Haystack Oncology for an undisclosed amount. This strategic move aims to integrate Haystack Oncology's highly sensitive minimal-residual disease (MRD) testing technology, which is based on circulating tumor DNA (ctDNA). Quest Diagnostics plans to leverage this technology in the development of innovative blood-based clinical laboratory services for solid tumor cancers, with availability expected to commence in 2024.

Major companies operating in the biopsy devices market include Becton Dickinson and Company (BD), Hologic, Inc., Danaher Corporation, Boston Scientific Corporation, Olympus Corporation, Cook Medical, Medtronic Inc, Cardinal Health, Argon Medical Devices Inc., Fujifilm Holdings Corp, BMA Co. Ltd., Transmed (China) Co., LTD, HaploX Biotechnology, Gene+sLab, Lepu Medical Technology, CMR Naviscan Corporation, DDD Diagnostics, Philips Healthcare, Siemens Healthineers, Abbott Laboratories, Bangs Laboratories Inc, Roche Diagnostics, Cepheid, Devicor Medical Products, Braile Biomedica Ltd, B.Braun Medical Gulf, Stryker ESCS BV.

North America was the largest region in the biopsy devices market in 2024. Asia-Pacific was the second largest region in the global biopsy devices market report share. The regions covered in the biopsy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopsy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Biopsy devices are utilized to obtain sample cells or tissues from a patient’s body for examination to ascertain the presence of a disease. They play a crucial role in diagnosing diseases, particularly cancer, by allowing healthcare professionals to analyze cellular structures and detect abnormal or cancerous cells.

Key product types within biopsy devices include needle-based biopsy instruments, core biopsy devices, aspiration biopsy needles, vacuum-assisted biopsy devices, biopsy forceps, and localization wires. Core biopsy devices utilize a large hollow needle to make a small incision in the skin over the lump. Imaging technologies associated with these devices include MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, and CT scan. Applications span breast biopsy, gynecological biopsy, prostate biopsy, liver biopsy, lung biopsy, kidney biopsy, gastroenterology biopsy, and others, with usage in diagnostics and imaging centers, hospitals, and similar medical settings.

The biopsy devices market research report is one of a series of new reports that provides biopsy devices market statistics, including biopsy devices industry global market size, regional shares, competitors with a biopsy devices market share, detailed biopsy devices market segments, market trends and opportunities, and any further data you may need to thrive in the biopsy devices industry. This biopsy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biopsy devices market consists of sales of core biopsy guns, core biopsy needles, aspiration biopsy needles, vacuum-assisted biopsy systems, vacuum-assisted biopsy needles, localization wires, procedure trays, and other biopsy devices that are used to diagnose various diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.